Premium
Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune‐mediated Neuropathies
Author(s) -
Fokkink WJR,
Koch BCP,
Ramakers CRB,
van Doorn PA,
van Gelder T,
Jacobs BC
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.693
Subject(s) - medicine , pharmacokinetics , pharmacodynamics , immune system , chronic inflammatory demyelinating polyneuropathy , antibody , regimen , immunoglobulin g , gastroenterology , immunology
The regimen for IVIg maintenance treatment varies considerably between patients with chronic immune‐mediated neuropathies. Although it is widely recognized that treatment regimens should be improved, detailed pharmacokinetics (PK) of IVIg have not yet been established. We aimed to determine the PK of IVIg maintenance treatment in patients with clinically stable, treatment‐dependent, chronic immune‐mediated neuropathy. Patients received a median IVIg dose of 30 g (range, 15–70 g) every 14 days (range, 7–28 days) resulting in high IgG peak levels (median, 25.9 g/L; range, 16.7–41.0 g/L) and trough levels (median, 16.1 g/L; range, 9.7–23.6 g/L). IgG PK parameters, including half‐life (median, 23.1 days; range, 11–60 days), were constant during subsequent courses in the same patients, but varied considerably between patients. The IgG levels at 1 week after infusion correlated with grip strength. These results provide insight into the PK of IVIg maintenance treatment in patients with chronic immune‐mediated neuropathies.